



Order ID A78052
 Provider Exagen Provider MD

Specimen
 Collected 06/28/2024
 Received 06/29/2024
Test Order
 Created 06/29/2024
 Reported 07/03/2024


Patient
Sample, Susan
 Gender - DOB Female - 05/17/1968
 Identifier Received
 Exagen ID 1082071

AVISE HCQ Test Report

Current Hydroxychloroquine (HCQ) Level:

1284.4 ng/mL - Supratherapeutic

Current HCQ Dose (mg/day)
 400



Risk Factors

Supratherapeutic: Excessive HCQ levels may arise from (1) chronic kidney disease stage (≥ 3 associated with higher odds), (2) HCQ dose (400 mg/day associated with higher odds compared to 200mg/day) and (3) substantial weight loss⁷.

Test Method Description

HCQ concentration is determined by liquid chromatography coupled with mass spectrometry (LC/MS/MS). This test has not been validated in pediatric populations. The HCQ blood level should be evaluated after 6 months of HCQ therapy - it has not been validated in patients treated for less than 6 months. This test cannot be used to assess the risk of HCQ toxicity.

References

1. Costedoat-Chalumeau N, et al. Arthritis Rheum. 2006 Oct;54(10):3284-90. doi: 10.1002/art.22156.
2. Costedoat-Chalumeau N, et al. Ann Rheum Dis. 2007 Jun;66(6):821-4. doi: 10.1136/ard.2006.067835.
3. Costedoat-Chalumeau N, et al. Ann Rheum Dis. 2013 Nov;72(11):1786-1792. doi: 10.1136/annrheumdis-2012-202322.
4. Costedoat-Chalumeau N, et al. Best Pract Res Clin Rheumatol. 2013 Jun;27(3):329-340. doi: 10.1016/j.berh.2013.07.001.
5. Frances C, et al. Arch Dermatol. 2012 Apr;148(4):479-84. doi: 10.1001/archdermatol.2011.2558.
6. Exagen Diagnostics, Inc. Data on File.
7. Garg S, et al. Arthritis Care Res. 2024 Feb;76(2):241-250. doi: 10.1002/acr.25228.
8. Petri M, et al. Arthritis Rheumatol. 2020 Mar; 72(3):448-453. doi: 10.1002/art.41121.



261 Liberty Way, Vista CA 92081
 CLIA# 05D1075048
 CAP# 7201051 | NYSDOH PFI# 8369

Laboratory Directors:
 Prashanti Reddy, M.D.

Provider Relations: 888.452.1522

AVISE and the AVISE and Exagen logos are registered trademarks of Exagen Inc. ©2024 All Rights Reserved

AVISE® tests are used for clinical purposes, not to be regarded as investigational or for research. Results are not intended to be used as the sole means for clinical diagnosis and patient management decisions. This test (AVISE HCQ) was developed, and performance characteristics were determined by Exagen Inc. as a Laboratory Developed Test (LDT). The Exagen laboratory is certified under the Clinical Laboratory Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP) as qualified to perform high-complexity clinical laboratory testing, and FDA approval or clearance is not necessary. SA1740 (7/24)